Key Insights

Highlights

Success Rate

90% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.9%

3 terminated out of 104 trials

Success Rate

90.3%

+3.8% vs benchmark

Late-Stage Pipeline

5%

5 trials in Phase 3/4

Results Transparency

18%

5 of 28 completed with results

Key Signals

5 with results90% success

Data Visualizations

Phase Distribution

59Total
Not Applicable (39)
Early P 1 (4)
P 1 (6)
P 2 (5)
P 3 (5)

Trial Status

Recruiting30
Completed28
Active Not Recruiting14
Unknown12
Not Yet Recruiting12
Withdrawn3

Trial Success Rate

90.3%

Benchmark: 86.5%

Based on 28 completed trials

Clinical Trials (104)

Showing 20 of 20 trials
NCT02912559Phase 3Active Not Recruiting

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

NCT07360834Not ApplicableNot Yet RecruitingPrimary

Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndrome

NCT07106359Not ApplicableRecruiting

Initial Testing of a Behavioral Intervention About Genetic Services for Families at Risk of Lynch Syndrome

NCT02359565Phase 1Active Not Recruiting

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

NCT04494945Not ApplicableRecruiting

Identifying and Caring for Individuals With Inherited Cancer Syndrome

NCT06914726Not ApplicableEnrolling By Invitation

Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes

NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT07304063Not ApplicableNot Yet RecruitingPrimary

Overcoming Barriers to Uptake of Cascade Screening

NCT07201012Not ApplicableRecruiting

Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome

NCT05419011Phase 2Active Not Recruiting

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

NCT03050268Recruiting

Familial Investigations of Childhood Cancer Predisposition

NCT04500548Phase 1Withdrawn

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

NCT07220239Not ApplicableRecruiting

Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome

NCT06126120CompletedPrimary

Colonoscopy Check-up in People With Lynch Syndrome

NCT05411718Phase 2Recruiting

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

NCT07609901Phase 3Not Yet RecruitingPrimary

Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers

NCT05410977Recruiting

Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients

NCT07600710Not Yet RecruitingPrimary

Periodontal Disease in Patients With Lynch Syndrome

NCT07542405Not ApplicableNot Yet Recruiting

A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families

NCT03124212Recruiting

Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland

Scroll to load more

Research Network

Activity Timeline